Topical and oral bexarotene

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma

(2012) J.J. Scarisbrick et al.   BRITISH JOURNAL OF DERMATOLOGY

Interactions of bexarotene (LGD1069, Targretin) with the coagulation system

(2011) Anne Hespel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations

(2011) Neha Mehta et al.   Clinical Lymphoma Myeloma & Leukemia

Primary cutaneous CD30 positive anaplastic large cell lymphoma – Report of a case treated with bexarotene

(2011) Ana Oliveira et al.   LEUKEMIA RESEARCH

Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation

(2011) M. Schlaak et al.   TRANSPLANT IMMUNOLOGY

Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

(2010) Cristina Muniesa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids

(2009) Antonino Musolino et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata

(2009) Rakhshandra Talpur et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma

(2008) N. Nieto-Rementería et al.   BRITISH JOURNAL OF DERMATOLOGY

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma

(2008) Ajith P. Kannangara et al.   JOURNAL OF DERMATOLOGICAL TREATMENT